Securing Orphan Drug and Fast Track Designations for Osteosarcoma and Soft Tissue Sarcoma
ADC Platform ConjuALL from RigaChemBio Applied, First Clinical Trial Planned Within This Year

RigaChemBio announced on September 28, 2026, that Sotio's SOT106, which utilizes the company's antibody-drug conjugate (ADC) platform, ConjuALL, has received Orphan Drug Designation for the treatment of soft tissue sarcoma and Fast Track Designation for the treatment of osteosarcoma from the U.S. Food and Drug Administration (FDA).


With these recent designations, SOT106 has now secured both Orphan Drug and Fast Track designations for two indications: osteosarcoma and soft tissue sarcoma. Previously, SOT106 received Orphan Drug Designation for osteosarcoma in May and Fast Track Designation for soft tissue sarcoma in August of this year.


Logo image of Rigachem Bio company. Rigachem Bio

Logo image of Rigachem Bio company. Rigachem Bio

View original image

SOT106 is an ADC developed by applying RigaChemBio’s ConjuALL platform to Sotio’s LRRC15-targeting antibody. It is engineered to remain stable in the bloodstream and selectively release its payload within the tumor microenvironment. In preclinical studies, including patient-derived xenograft models of osteosarcoma and soft tissue sarcoma, SOT106 demonstrated both anti-tumor activity and tolerability.


Radek Spisek, CEO of Sotio, commented, “This additional designation marks another important milestone for SOT106,” adding, “Patients with sarcomas still face limited treatment options and there is a need for innovative targeted therapies.”


Park Sejin, CEO of RigaChemBio, stated, “With SOT106 sequentially securing regulatory designations from the FDA for both sarcoma indications, the competitiveness of our ConjuALL platform has once again been proven. We will work closely with our partner to ensure seamless progress into clinical trials.”


The Fast Track and Orphan Drug designation programs are initiatives operated by the FDA to support the development of treatments for serious diseases or those with high unmet medical need. These programs offer benefits such as enhanced communication with the FDA and expedited review processes. Sotio plans to initiate the first human clinical trials of SOT106 within this year.



RigaChemBio signed a technology transfer agreement for its ADC platform with Sotio in November 2021. Through this agreement, Sotio secured global development and commercialization rights for multi-target ADC therapies utilizing the ConjuALL platform. SOT106 is the first ADC candidate derived as a result of this partnership.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing